Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Outsources Drug Discovery Research To BioDuro For Respiratory And Inflammation Indications

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - AstraZeneca is expanding its research collaboration with contract research organization BioDuro to cooperate on drug discovery research in respiratory and inflammation diseases in China, the two companies announced March 23
Advertisement

Related Content

Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
Looking At The Universe Of Possibilities In China: An Interview With Eli Lilly China R&D Head Tony Zhang
China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
China Offers Playground Of Opportunity For Trying Out Different Models, Risks - Shanghai R&D Summit
Chinese Tigermed Forms CRO Partnerships In Korea, Russia
Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech
Chinese CRO Alliance Sets Eyes On Europe
China’s WuXi To Acquire U.S.-Based AppTec Laboratory Services
China’s Hutchison MediPharma Freezes Development Of Cancer Drug, Signs Development Deal With Janssen
Advertisement
UsernamePublicRestriction

Register

SC071194

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel